Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma

[1]  Dong Zhou,et al.  Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a nationwide study , 2020, Hepatology International.

[2]  R. Lencioni,et al.  mRECIST for HCC: Performance and novel refinements. , 2020, Journal of hepatology.

[3]  Chia-Chang Hsu,et al.  Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma , 2019, Medicine.

[4]  J. H. Kim,et al.  Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: A nationwide study , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[5]  H. Friess,et al.  Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study , 2019, Gut.

[6]  Ming‐Lung Yu,et al.  Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection , 2018, PloS one.

[7]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[8]  A. Gasbarrini,et al.  Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice , 2018, Hepatology.

[9]  Ming‐Lung Yu,et al.  The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment , 2018, The Kaohsiung journal of medical sciences.

[10]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[11]  Ming‐Lung Yu,et al.  Impact of tumor size on the prognosis of hepatocellular carcinoma in patients who underwent liver resection , 2017, Journal of the Chinese Medical Association : JCMA.

[12]  J. Bruix,et al.  Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. , 2017, Journal of hepatology.

[13]  M. Ho,et al.  Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. , 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

[14]  K. Nan,et al.  Hepatocellular carcinoma in elderly: Clinical characteristics, treatments and outcomes compared with younger adults , 2017, PloS one.

[15]  C. la Vecchia,et al.  Global trends and predictions in hepatocellular carcinoma mortality. , 2017, Journal of hepatology.

[16]  M. Kudo,et al.  Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update , 2017, Hepatology International.

[17]  S. Choi,et al.  Barcelona clinic liver cancer-stage C hepatocellular carcinoma , 2017, Medicine.

[18]  H. El‐Serag,et al.  Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. , 2016, Journal of hepatology.

[19]  M. Kudo,et al.  Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. , 2016, Journal of hepatology.

[20]  H. Nagano,et al.  Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014) , 2016, Liver Cancer.

[21]  J. Blanc,et al.  Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C results from a French multicenter study , 2015, European journal of gastroenterology & hepatology.

[22]  D. Sinn,et al.  Different Survival of Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Patients by the Extent of Portal Vein Invasion and the Type of Extrahepatic Spread , 2015, PloS one.

[23]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[24]  S. Fan,et al.  Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. , 2014, Gastroenterology.

[25]  Y. Osaki,et al.  Treatment for Hepatocellular Carcinoma in Elderly Patients: A Literature Review , 2013, Journal of Cancer.

[26]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. , 2012, European journal of cancer.

[27]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[28]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[29]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[30]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[31]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.